Form 4: Shattuck Labs Director Helen Boudreau Receives 33,150 Stock Options

Shattuck Labs, Inc. Director Helen M. Boudreau was granted 33,150 stock options with an exercise price of $0.82, vesting on the earlier of one year from the grant date or the next annual meeting.

Summary

• Helen M. Boudreau, a Director of Shattuck Labs, Inc. (STTK), was granted 33,150 stock options.
• The options have an exercise price of $0.82 per share.
• The grant date for these options was July 14, 2025.
• The options will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders.
• The vesting is contingent upon Ms. Boudreau's continued service to Shattuck Labs, Inc.
• The options have an expiration date of July 14, 2035.
• Following this transaction, Ms. Boudreau beneficially owns 33,150 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of alignment between management and shareholder interests, incentivizing long-term performance. It's a standard compensation practice and generally viewed favorably.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Risks

• The value of the stock options is dependent on the future performance of Shattuck Labs, Inc.'s common stock, which is subject to market fluctuations and company-specific risks.
• The options' vesting is subject to the director's continued service, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The granted stock options will vest in full on the earlier of the one-year anniversary of the grant date (July 14, 2026) or immediately prior to Shattuck Labs, Inc.'s next annual meeting of stockholders, provided the reporting person continues her service to the Issuer.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Shattuck Labs, Inc., to attract and retain experienced board members and align their incentives with long-term company growth and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• While specific comparable companies or projects are not detailed in this filing, similar equity grants are observed at peers such as CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT) for their non-employee directors, often tied to service and performance.
• The exercise price of $0.82 is likely based on the market price of STTK common stock on the grant date, which is a standard method for option pricing.

Corporate Governance

Related Party Transactions

• The grant of stock options to Helen M. Boudreau, a Director of Shattuck Labs, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially leading to better long-term performance. Potential future dilution from option exercise is an expected impact.
• Employees: No direct impact on general employees is noted.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is noted.

Next Steps

• The stock options will vest on the earlier of July 14, 2026 (one-year anniversary of grant) or immediately prior to the Issuer's next annual meeting of stockholders.
• Helen M. Boudreau's continued service to Shattuck Labs, Inc. is required for the options to vest.

Key Dates

Recommendation

Keywords

Shattuck Labs, STTK, Helen Boudreau, stock options, director compensation, SEC Form 4, insider transaction, equity grant, beneficial ownership